查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1718265

核酸治療 CDMO 市場（按治療類型、服務類型、治療應用和最終用戶分類）—2025 年至 2030 年全球預測

Nucleic Acid Therapeutics CDMO Market by Therapeutics Type, Service Type, Therapeutic Applications, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年核酸治療CDMO市場價值將達107.7億美元，2025年將成長至120億美元，複合年成長率為11.42%，到2030年將達到206.2億美元。

主要市場統計數據
基準年2024年 107.7億美元
預計2025年 120億美元
預測年份 2030 206.2億美元
複合年成長率（%） 11.42%

核酸療法已成為重新定義現代醫學的革命性方法。受託製造廠商(CDMO) 格局正在快速發展，以滿足先進基因療法和突破性醫療治療設定的嚴格標準。最近的科學突破，加上不斷擴大的法律規範，迫切需要創新和專業製造服務。強大的分析測試、精確的品管和客製自訂製造解決方案的整合使這些組織能夠支持基於 DNA 和 RNA 的治療方法的複雜需求。

此外，遺傳疾病、感染疾病和腫瘤學領域治療應用的不斷擴大表明，研究突破與臨床需求之間存在著密切的交集。這個市場故事不僅強調了學術界、生物技術和製藥產業之間合作夥伴關係的重要性，也強調了調整傳統製造方法以適應新型生物治療分子的重要性。隨著市場基本面的變化，決策者正在考慮利用新技術和最佳化生產效率的機會。

核酸療法的發展既帶來了挑戰，也帶來了巨大的機會。隨著對精確度、可擴展性和快速創新的需求不斷成長，CDMO 在科學創造力和製造專業知識的融合中佔據著獨特的地位。這項全面的研究對市場區隔、區域動態和主要產業參與者的影響提供了深入的見解，提供了支持策略決策的權威概述。

核酸治療領域變革

在科學創新、數位轉型和不斷變化的法規環境的推動下，核酸治療市場正在發生巨大變化。傳統的藥物開發模式正在被敏捷製造流程和整合技術解決方案重新定義。 RNA 和 DNA 療法研發步伐的加快需要能夠提供高效可靠產品的新製造方法。

相關人員正在見證從傳統小分子製造到更細緻的生物製造策略的轉變。這項轉變將以採用先進的分析平台和增強的製程控制系統為標誌，以確保精確的品管。此外，涉及基因編輯和傳訊RNA技術的治療方法的快速擴展正在推動對靈活、強大的製造夥伴關係關係的需求，這些合作夥伴關係可以在保持法規遵從性的同時快速擴大生產規模。

同時，市場正在擁抱研究和生產方法的數位轉型。雲端基礎的數據分析和即時監控正在整合到生產工作流程中，從而實現主動調整和持續改進。這些變化大大縮短了上市時間，並克服了生技藥品製造中固有的一些傳統瓶頸，將該領域推向了新的高度。

競爭因素正在重新定義競爭格局。這種轉變不僅是技術上的，也是文化上的，需要重新關注協作、風險管理和對尖端製造基礎設施的策略性投資。

市場區隔洞察推動市場創新

以細分市場分析核酸治療市場，可以發現其多方面的結構，可滿足不同的需求和專業知識。市場按治療劑類型細分，涵蓋 DNA 和 RNA 模式。雖然 DNA 療法傳統上具有穩定性和良好的記錄，但 RNA 療法具有快速的開發週期和可調節的基因表現，並不斷突破界限。這兩條路徑代表了既定協議和新創新之間的策略平衡。

按服務類型細分進一步闡明了分析測試和品管、製造、包裝和分銷以及流程開發和最佳化等領域。每個服務類別在確保治療不僅有效且可靠方面發揮著至關重要的作用。隨著監管機構實施更嚴格的標準，分析測試和品管變得越來越重要，並且透過精密工程和自動化的整合來增強製造能力。包裝和分銷，加上工藝開發，提供了從實驗室創新到患者交付的無縫連續性。

在考慮治療應用時，可以從各種臨床學科中得出見解，包括遺傳學、感染疾病、神經病學、腫瘤學和罕見疾病。每個應用領域都有其自身的挑戰和機會，推動我們的研究和開發策略。例如，腫瘤學和神經系統疾病治療模式的不斷發展促使人們重新審視傳統的藥物傳遞系統，並鼓勵創造新的、有針對性的干涉措施。

此外，按學術和研究機構、生物技術公司和製藥公司的最終用戶細分，顯示核酸療法被廣泛採用。學術界推動基礎研究，而生物技術則迅速將研究發現轉化為臨床應用。同時，製藥公司正在將這些創新推向全球市場，以確保在日益激烈的競爭環境中獲得產品並實現永續成長。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球遺傳疾病的盛行率不斷上升
      • 個人化醫療和標靶基因治療的需求不斷增加
      • 擴大製藥和生技領域的研發活動
    • 限制因素
      • 嚴守核酸藥物生產相關規定
    • 機會
      • 利用先進的核酸穩定技術和分析測試平台在 CDMO 環境中實現先進的治療應用
      • 持續開發基於 mRNA 的疫苗和療法
    • 任務
      • 核酸藥物研發專業人才短缺
  • 市場區隔分析
    • 服務類型：人們對純度和效力的分析測試以及品管服務的興趣日益濃厚
    • 最終用戶：核酸治療CDMO在學術研究機構的應用不斷擴大
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 核酸治療 CDMO 市場（依治療類型）

  • DNA治療公司
  • RNA治療學

第7章 核酸治療 CDMO 市場（依服務類型）

  • 分析測試和品管
  • 製造業
  • 包裝和運輸
  • 製程開發與最佳化

8. 核酸治療CDMO市場治療應用

  • 遺傳性疾病
  • 感染疾病
  • 神經系統疾病
  • 腫瘤學
  • 罕見疾病

第9章 核酸治療 CDMO 市場（依最終使用者）

  • 學術研究所
  • 生技公司
  • 製藥公司

10.美洲核酸治療CDMO市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

11. 亞太地區核酸治療CDMO市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12. 歐洲、中東和非洲核酸治療 CDMO 市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • AGC Biologics Inc.
  • Agilent Technologies, Inc.
  • Ajinomoto Bio-Pharma Services
  • Almac Group Ltd.
  • Biomay AG
  • BioSpring GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CordenPharma International GmbH
  • Creative Biogene
  • Danaher Corporation
  • Eurofins Scientific SE
  • Evonik Industries AG
  • GenScript Biotech Corporation
  • Lonza Group Ltd.
  • Polypeptide Group AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • The Scripps Research Institute
  • Touchlight Group
  • Univercells Group
  • WuXi AppTec Co., Ltd.
Product Code: MRR-CA7E340319CD

The Nucleic Acid Therapeutics CDMO Market was valued at USD 10.77 billion in 2024 and is projected to grow to USD 12.00 billion in 2025, with a CAGR of 11.42%, reaching USD 20.62 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 10.77 billion
Estimated Year [2025] USD 12.00 billion
Forecast Year [2030] USD 20.62 billion
CAGR (%) 11.42%

Nucleic acid therapeutics have emerged as transformative modalities redefining modern medicine. The landscape of contract development and manufacturing organizations (CDMOs) is rapidly evolving to meet the rigorous standards set by advanced gene therapies and revolutionary treatments. Recent scientific breakthroughs, combined with an expanding regulatory framework, have driven both innovation and an urgent need for specialized manufacturing services. The integration of robust analytical testing, precision quality control, and custom manufacturing solutions has enabled these organizations to support the complex demands of DNA- and RNA-based therapies.

Furthermore, the expansion of therapeutic applications across genetic disorders, infectious diseases, and oncology demonstrates a keen intersection between research breakthroughs and clinical needs. This market narrative not only highlights the importance of collaborative partnerships across academia, biotechnology, and pharmaceutical industries but also underscores the significance of adapting traditional manufacturing methodologies to handle novel biotherapeutic molecules. As market fundamentals shift, decision-makers are examining opportunities to leverage new technologies and optimize production efficiency.

The evolution of nucleic acid therapeutics presents both challenges and substantial opportunities. With increasing demands for precision, scalability, and rapid innovation, CDMOs are positioned uniquely at the confluence of scientific creativity and production expertise. This comprehensive exploration sets the stage for in-depth insights into market segmentation, regional dynamics, and the influence of key industry players, providing an authoritative overview structured to support strategic decision-making.

Transformative Shifts Reshaping the Nucleic Acid Therapeutics Landscape

The nucleic acid therapeutics market is experiencing dramatic shifts driven by scientific innovation, digital transformation, and evolving regulatory environments. Traditional drug development paradigms are being redefined by agile manufacturing processes and integrated technology solutions. The accelerating pace of RNA and DNA therapeutic discovery has necessitated new production methodologies that can deliver products with both high efficacy and reliability.

Stakeholders are witnessing a transition from conventional small molecule production to more nuanced biological manufacturing strategies. This transformation is characterized by the adoption of advanced analytical platforms and enhanced process control systems that ensure precise quality control. Moreover, the rapid expansion of therapeutic modalities, including gene editing and messenger RNA technologies, has driven demand for agile and robust manufacturing partnerships capable of scaling production swiftly while maintaining regulatory compliance.

Simultaneously, the marketplace is embracing the digital transformation of research and production methods. Cloud-based data analytics and real-time monitoring are being integrated into production workflows, enabling proactive adjustments and continuous improvement. These changes are propelling the sector to greater heights by significantly reducing time-to-market and overcoming some of the traditional bottlenecks inherent in biologics manufacturing.

Collectively, these factors are redefining competitive strategies across the landscape. The shift is not simply technological but cultural, demanding a renewed focus on collaboration, risk management, and strategic investment in state-of-the-art manufacturing infrastructure.

Key Segmentation Insights Driving Market Innovation

The segmented analysis of the nucleic acid therapeutics market reveals a multifaceted structure that caters to diverse needs and specialized capabilities. The market is dichotomized by therapeutics type, studying both DNA and RNA modalities. DNA therapeutics have traditionally provided stability and a proven track record, while RNA therapeutics continue to push boundaries, offering rapid development cycles and tunable gene expression. This dual pathway represents a strategic balance between established protocols and emerging innovations.

Service type segmentation further illuminates areas such as analytical testing and quality control, manufacturing, packaging and distribution, and process development and optimization. Each service category plays a pivotal role in ensuring therapies are not only effective but also reliably delivered. Analytical testing and quality control have become increasingly critical as regulatory bodies enforce stricter criteria, while manufacturing capabilities are being enhanced by the integration of precision engineering and automation. Packaging and distribution, coupled with process development, provide a seamless continuum from laboratory innovation to patient delivery.

When examining therapeutic applications, insights are drawn from various clinical sectors including genetic disorders, infectious diseases, neurological disorders, oncology, and rare disorders. Each application area carries unique challenges and opportunities that drive tailored research and development strategies. The evolution of treatment paradigms in oncology and neurological disorders, for instance, is prompting a re-examination of traditional drug delivery systems and inspiring the creation of novel, targeted interventions.

Moreover, the segment based on end users-spanning academic and research institutes, biotechnology firms, and pharmaceutical companies-exemplifies the extensive reach of nucleic acid therapies. The academic realm propels foundational research, while the biotechnology sector rapidly translates discoveries into clinical applications. Pharmaceutical companies, on the other hand, bring these innovations to a global market, ensuring accessibility and sustained growth in an increasingly competitive environment.

Based on Therapeutics Type, market is studied across DNA Therapeutics and RNA Therapeutics.

Based on Service Type, market is studied across Analytical Testing & Quality Control, Manufacturing, Packaging & Distribution, and Process Development & Optimization.

Based on Therapeutic Applications, market is studied across Genetic Disorders, Infectious Diseases, Neurological Disorders, Oncology, and Rare Disorders.

Based on End User, market is studied across Academic & Research Institutes, Biotechnology Firms, and Pharmaceutical Companies.

Key Regional Insights Across Global Markets

The global perspective of nucleic acid therapeutics uncovers significant regional variations that highlight both unique opportunities and sector-specific challenges. In the Americas, advanced research infrastructures and a robust funding environment have fostered an ecosystem where innovation thrives alongside regulatory excellence. This region continues to lead in terms of clinical trials and state-of-the-art manufacturing facilities, making it a hotspot for next-generation therapeutic discovery and production.

Across Europe, the Middle East, and Africa, there is a pronounced emphasis on harmonizing regulatory standards while fostering an environment conducive to public-private partnerships. European markets, in particular, are noted for stringent compliance and quality benchmarks, which drive industry standards upward. The Middle East and Africa are witnessing increasing investments in biotechnological research, motivated by a growing need to address regional health challenges and tap into emerging talent pools. This diverse region articulates a unique blend of legacy expertise and innovative agility.

In Asia-Pacific, rapid economic development and substantial investments in research and development are redefining the landscape. The region benefits from a mix of established industrial bases and nimble start-ups, which together contribute to a competitive production and innovation environment. The surge in regulatory reforms is further catalyzing innovation, ensuring that manufacturing processes keep pace with global benchmarks. This dynamic region not only supports large-scale clinical development but also serves as a critical hub for supply chain optimization and operational excellence across the nucleic acid therapeutics market.

These region-specific insights reinforce the view that a one-size-fits-all approach is untenable. Instead, tailored strategies that account for local market dynamics, resource availability, and regulatory environments are essential for tapping the diverse global potential of nucleic acid therapeutics.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Leading the Charge in Therapeutics Innovation

The competitive landscape is defined by a cadre of leading companies whose innovative approaches are setting new standards in the nucleic acid therapeutics market. Firms such as AGC Biologics Inc. and Agilent Technologies, Inc. are recognized for their commitment to integrating advanced analytics with meticulous quality control processes. Ajinomoto Bio-Pharma Services and Almac Group Ltd. have carved out reputations for excellence in manufacturing and process optimization, consistently delivering reliable solutions that meet rigorous industry standards.

Equally influential are organizations like Biomay AG and BioSpring GmbH, which have leveraged cutting-edge technologies to optimize both packaging and distribution channels. Catalent, Inc. and Charles River Laboratories International, Inc. have been instrumental in refining manufacturing protocols and streamlining analytical testing methodologies that enhance overall product reliability. Industry leaders such as CordenPharma International GmbH and Creative Biogene exemplify the ability to balance high-volume production with precision customization.

Danaher Corporation and Eurofins Scientific SE further underscore the critical role of innovative testing and quality assurance procedures, while companies including Evonik Industries AG and GenScript Biotech Corporation have accelerated process development and optimization. Lonza Group Ltd. and Polypeptide Group AG stand out for their scalable manufacturing solutions, ensuring seamless transitions from bench to market. Other key players, including Recipharm AB and Rentschler Biopharma SE, have continued to drive efficiency and innovation in both traditional and next-generation therapeutic production.

Samsung Biologics and The Scripps Research Institute illustrate the vital interconnectedness of research and manufacturing, a trait shared by Touchlight Group, Univercells Group, and WuXi AppTec Co., Ltd. Their combined efforts are not only redefining production paradigms but are also instrumental in pushing the boundaries of what is scientifically and commercially possible in the realm of nucleic acid therapeutics.

The report delves into recent significant developments in the Nucleic Acid Therapeutics CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics Inc., Agilent Technologies, Inc., Ajinomoto Bio-Pharma Services, Almac Group Ltd., Biomay AG, BioSpring GmbH, Catalent, Inc., Charles River Laboratories International, Inc., CordenPharma International GmbH, Creative Biogene, Danaher Corporation, Eurofins Scientific SE, Evonik Industries AG, GenScript Biotech Corporation, Lonza Group Ltd., Polypeptide Group AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, The Scripps Research Institute, Touchlight Group, Univercells Group, and WuXi AppTec Co., Ltd.. Actionable Recommendations for Industry Leaders in Therapeutics

Industry leaders must adopt a multidimensional strategy to navigate the shifting landscape of nucleic acid therapeutics effectively. It is crucial to invest in state-of-the-art manufacturing infrastructure, ensuring seamless integration of digital analytics with process automation. Firms should proactively engage with regulatory bodies to remain ahead of compliance curves, thus securing a competitive edge in innovation and market penetration.

Collaboration remains a powerful tool in this sector. Establishing strategic partnerships with research institutions, biotechnology innovators, and global pharmaceutical companies can help accelerate product development and broaden market reach. Emphasis on robust risk management strategies, coupled with the adoption of advanced manufacturing platforms, will serve as catalysts for operational excellence. Leaders in the field are encouraged to leverage emerging technologies that promise enhanced scalability and faster time-to-market, aligning production capabilities with the rapidly evolving clinical demands.

Lastly, maintaining an agile mindset is critical as market dynamics continue to evolve. Organizations that invest in continual improvement and foster an environment of cross-disciplinary innovation will be best positioned to capitalize on the emerging opportunities within this space.

Conclusion: Embracing Change in Nucleic Acid Therapeutics

In conclusion, the advancement of nucleic acid therapeutics represents a significant leap forward in modern medicine. The market is witnessing an era of transformative change, driven by innovative scientific breakthroughs, strategic segmentation insights, and a competitive ecosystem dominated by leading industry players. The evolving landscape requires a nuanced understanding of the interplay between technology, regulation, and market dynamics.

This comprehensive analysis underscores the importance of adopting forward-thinking strategies and leveraging global insights to build resilient and efficient production pipelines. The future of nucleic acid therapeutics lies in the hands of those who not only embrace change but also proactively drive its evolution through innovation, collaboration, and strategic investment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of genetic disorders globally
      • 5.1.1.2. Rising demand for personalized medicine and targeted gene therapies
      • 5.1.1.3. Expansion of research and development activities in pharmaceutical and biotechnology sectors
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory compliance in production of nucleic acid therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging advanced nucleic acid stabilization techniques and analytical testing platforms for advanced therapeutic applications in CDMO settings
      • 5.1.3.2. Ongoing development of mRNA-based vaccines and therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled professionals specialized in nucleic acid therapeutics development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Service Type: Increasing preference for analytical testing & quality control services for their purity, and potency
    • 5.2.2. End User: Expanding utilization of nucleic acid therapeutics CDMO in academic & research institutes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Nucleic Acid Therapeutics CDMO Market, by Therapeutics Type

  • 6.1. Introduction
  • 6.2. DNA Therapeutics
  • 6.3. RNA Therapeutics

7. Nucleic Acid Therapeutics CDMO Market, by Service Type

  • 7.1. Introduction
  • 7.2. Analytical Testing & Quality Control
  • 7.3. Manufacturing
  • 7.4. Packaging & Distribution
  • 7.5. Process Development & Optimization

8. Nucleic Acid Therapeutics CDMO Market, by Therapeutic Applications

  • 8.1. Introduction
  • 8.2. Genetic Disorders
  • 8.3. Infectious Diseases
  • 8.4. Neurological Disorders
  • 8.5. Oncology
  • 8.6. Rare Disorders

9. Nucleic Acid Therapeutics CDMO Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Biotechnology Firms
  • 9.4. Pharmaceutical Companies

10. Americas Nucleic Acid Therapeutics CDMO Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Nucleic Acid Therapeutics CDMO Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Nucleic Acid Therapeutics CDMO Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Maravai LifeSciences broadens its nucleic acid therapeutics pipeline by acquiring Officinae Bio's DNA and RNA business
    • 13.3.2. GSK forges strategic licensing deal with Touchlight to access advanced doggybone DNA technology
    • 13.3.3. FUJIFILM Toyama Chemical and Synplogen Forge Alliance to Enhance mRNA Therapeutics Production
    • 13.3.4. Exothera Launches Advanced RNA Therapeutics Platform 'Ntensify' in North America, Streamlining Nucleic Acid Drug Development
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AGC Biologics Inc.
  • 2. Agilent Technologies, Inc.
  • 3. Ajinomoto Bio-Pharma Services
  • 4. Almac Group Ltd.
  • 5. Biomay AG
  • 6. BioSpring GmbH
  • 7. Catalent, Inc.
  • 8. Charles River Laboratories International, Inc.
  • 9. CordenPharma International GmbH
  • 10. Creative Biogene
  • 11. Danaher Corporation
  • 12. Eurofins Scientific SE
  • 13. Evonik Industries AG
  • 14. GenScript Biotech Corporation
  • 15. Lonza Group Ltd.
  • 16. Polypeptide Group AG
  • 17. Recipharm AB
  • 18. Rentschler Biopharma SE
  • 19. Samsung Biologics
  • 20. The Scripps Research Institute
  • 21. Touchlight Group
  • 22. Univercells Group
  • 23. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET MULTI-CURRENCY
  • FIGURE 2. NUCLEIC ACID THERAPEUTICS CDMO MARKET MULTI-LANGUAGE
  • FIGURE 3. NUCLEIC ACID THERAPEUTICS CDMO MARKET RESEARCH PROCESS
  • FIGURE 4. NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NUCLEIC ACID THERAPEUTICS CDMO MARKET DYNAMICS
  • TABLE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 194. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2024